FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891728857> ?p ?o ?g. }

• W2891728857 endingPage "5590" @default.
• W2891728857 startingPage "5577" @default.
• W2891728857 abstract "PPARgamma agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies Marcelle Silva-Abreu,1,2 Ana Cristina Calpena,1,2 Pol Andrés-Benito,3,4 Ester Aso,3,4 Ignacio A Romero,5 David Roig-Carles,5 Radka Gromnicova,5 Marta Espina,1,2 Isidre Ferrer,3,4 María Luisa García,1,2 David Male5 1Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain; 2Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain; 3Servei d’Anatomia Patològica, Institut d’Investigació Biomèdica de Bellvitge-Hospital Universitari de Bellvitge, Universitat de Barcelona, L’Hospitalet de Llobregat, Spain; 4Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain; 5School of Life, Health and Chemical Sciences, Faculty of Science, The Open University, Walton Hall, Milton Keynes, UK Objective: The first aim of this study was to develop a nanocarrier that could transport the peroxisome proliferator-activated receptor agonist, pioglitazone (PGZ) across brain endothelium and examine the mechanism of nanoparticle transcytosis. The second aim was to determine whether these nanocarriers could successfully treat a mouse model of Alzheimer’s disease (AD). Methods: PGZ-loaded nanoparticles (PGZ-NPs) were synthesized by the solvent displacement technique, following a factorial design using poly (lactic-co-glycolic acid) polyethylene glycol (PLGA-PEG). The transport of the carriers was assessed in vitro, using a human brain endothelial cell line, cytotoxicity assays, fluorescence-tagged nanocarriers, fluorescence-activated cell sorting, confocal and transmission electron microscopy. The effectiveness of the treatment was assessed in APP/PS1 mice in a behavioral assay and by measuring the cortical deposition of β-amyloid. Results: Incorporation of PGZ into the carriers promoted a 50x greater uptake into brain endothelium compared with the free drug and the carriers showed a delayed release profile of PGZ in vitro. In the doses used, the nanocarriers were not toxic for the endothelial cells, nor did they alter the permeability of the blood–brain barrier model. Electron microscopy indicated that the nanocarriers were transported from the apical to the basal surface of the endothelium by vesicular transcytosis. An efficacy test carried out in APP/PS1 transgenic mice showed a reduction of memory deficit in mice chronically treated with PGZ-NPs. Deposition of β-amyloid in the cerebral cortex, measured by immunohistochemistry and image analysis, was correspondingly reduced. Conclusion: PLGA-PEG nanocarriers cross brain endothelium by transcytosis and can be loaded with a pharmaceutical agent to effectively treat a mouse model of AD. Keywords: nanoparticle, Alzheimer’s disease, blood–brain barrier, brain endothelium, pioglitazone, APP/PS1 transgenic mouse" @default.
• W2891728857 created "2018-09-27" @default.
• W2891728857 creator A5009795950 @default.
• W2891728857 creator A5010636987 @default.
• W2891728857 creator A5013851751 @default.
• W2891728857 creator A5023989324 @default.
• W2891728857 creator A5026860985 @default.
• W2891728857 creator A5037988586 @default.
• W2891728857 creator A5046440462 @default.
• W2891728857 creator A5051897861 @default.
• W2891728857 creator A5071058898 @default.
• W2891728857 creator A5077918506 @default.
• W2891728857 creator A5087696327 @default.
• W2891728857 date "2018-09-01" @default.
• W2891728857 modified "2023-10-18" @default.
• W2891728857 title "PPAR&gamma; agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer&rsquo;s disease: in vitro and in vivo studies" @default.
• W2891728857 cites W1493421249 @default.
• W2891728857 cites W1553061387 @default.
• W2891728857 cites W1554596985 @default.
• W2891728857 cites W1966116864 @default.
• W2891728857 cites W1970613754 @default.
• W2891728857 cites W1982471389 @default.
• W2891728857 cites W1993760429 @default.
• W2891728857 cites W1995336204 @default.
• W2891728857 cites W1995718072 @default.
• W2891728857 cites W1996384040 @default.
• W2891728857 cites W1997364324 @default.
• W2891728857 cites W1999856629 @default.
• W2891728857 cites W2003109394 @default.
• W2891728857 cites W2006505402 @default.
• W2891728857 cites W2010256443 @default.
• W2891728857 cites W2011005493 @default.
• W2891728857 cites W2012525940 @default.
• W2891728857 cites W2013528575 @default.
• W2891728857 cites W2027876233 @default.
• W2891728857 cites W2054164797 @default.
• W2891728857 cites W2062214806 @default.
• W2891728857 cites W2065172289 @default.
• W2891728857 cites W2085921260 @default.
• W2891728857 cites W2094530411 @default.
• W2891728857 cites W2107798346 @default.
• W2891728857 cites W2113972541 @default.
• W2891728857 cites W2122181073 @default.
• W2891728857 cites W2134177573 @default.
• W2891728857 cites W2134387783 @default.
• W2891728857 cites W2136348158 @default.
• W2891728857 cites W2144475530 @default.
• W2891728857 cites W2157026347 @default.
• W2891728857 cites W2235679952 @default.
• W2891728857 cites W2279234267 @default.
• W2891728857 cites W2327589931 @default.
• W2891728857 cites W2337531481 @default.
• W2891728857 cites W2402092843 @default.
• W2891728857 cites W2444197879 @default.
• W2891728857 cites W2494973102 @default.
• W2891728857 cites W2507919919 @default.
• W2891728857 cites W2517249974 @default.
• W2891728857 cites W2564564443 @default.
• W2891728857 cites W2566571485 @default.
• W2891728857 cites W2572193318 @default.
• W2891728857 cites W2581117202 @default.
• W2891728857 cites W2619305773 @default.
• W2891728857 cites W2636979619 @default.
• W2891728857 cites W2723709131 @default.
• W2891728857 cites W2757601767 @default.
• W2891728857 cites W2769313758 @default.
• W2891728857 cites W2781624108 @default.
• W2891728857 doi "https://doi.org/10.2147/ijn.s171490" @default.
• W2891728857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6154713" @default.
• W2891728857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30271148" @default.
• W2891728857 hasPublicationYear "2018" @default.
• W2891728857 type Work @default.
• W2891728857 sameAs 2891728857 @default.
• W2891728857 citedByCount "49" @default.
• W2891728857 countsByYear W28917288572018 @default.
• W2891728857 countsByYear W28917288572019 @default.
• W2891728857 countsByYear W28917288572020 @default.
• W2891728857 countsByYear W28917288572021 @default.
• W2891728857 countsByYear W28917288572022 @default.
• W2891728857 countsByYear W28917288572023 @default.
• W2891728857 crossrefType "journal-article" @default.
• W2891728857 hasAuthorship W2891728857A5009795950 @default.
• W2891728857 hasAuthorship W2891728857A5010636987 @default.
• W2891728857 hasAuthorship W2891728857A5013851751 @default.
• W2891728857 hasAuthorship W2891728857A5023989324 @default.
• W2891728857 hasAuthorship W2891728857A5026860985 @default.
• W2891728857 hasAuthorship W2891728857A5037988586 @default.
• W2891728857 hasAuthorship W2891728857A5046440462 @default.
• W2891728857 hasAuthorship W2891728857A5051897861 @default.
• W2891728857 hasAuthorship W2891728857A5071058898 @default.
• W2891728857 hasAuthorship W2891728857A5077918506 @default.
• W2891728857 hasAuthorship W2891728857A5087696327 @default.
• W2891728857 hasBestOaLocation W28917288571 @default.
• W2891728857 hasConcept C150903083 @default.
• W2891728857 hasConcept C178855305 @default.
• W2891728857 hasConcept C18150654 @default.
• W2891728857 hasConcept C185592680 @default.
• W2891728857 hasConcept C202751555 @default.

• next